
NAME: Debra Patt, MD, PhD, MBA

INSTITUTION: Texas Oncology

OPEN SEAT: Society Board of Directors Designated Community Oncologist

A. EDUCATION, POSTDOCTORAL TRAINING, LICENSURE & CERTIFICATION

Education:

2020	Ph.D.	The University of Texas School of Public Health (Health Economics and Health Services Research) Research on "Evaluating the impact on clinical decision support systems to nudge compliance with evidence-based pathways in patients with cancer by using mixed effects models."
2014	M.B.A.	The University of Texas at Austin, McCombs School of Business (Business Administration)
2006	M.P.H.	The University of Texas School of Public Health (Management and Policy Sciences)
2005		National Cancer Institute, Summer Fellowship Program in Cancer Prevention
2003-2006		MD Anderson Cancer Center, Fellowship in Hematology and Medical Oncology
1999-2003		Residency, Internal Medicine and Pediatrics, Baylor College of Medicine
1999	M.D.	Baylor College of Medicine
1995	B.S.	The University of Texas at Austin (Zoology Plan I Honors Program)

Certificates:

2022	Clinical Informatics Certified
2017	American Board of Internal Medicine Oncology Specialty Exam Recertification
2007	American Board of Internal Medicine, Hematology Specialty Exam
2006	American Board of Internal Medicine, Oncology Specialty Exam
2003	American Board of Internal Medicine
2003	Texas State Medical License

B. EXPERIENCE AND RESEARCH

Experience:

2015-	<p>Executive Vice President, Texas Oncology, Policy and Strategic Initiatives</p> <p><i>Public Policy:</i> Guide and direct public policy at State and Federal Level to improve cancer care. Testified before Congress E&C against Medicare part B pilot program, which was later rescinded. Meet with policy makers as appropriate. Manage relationships to support collaborative business agreements and with external stakeholders: ASCO, COA, TMA, AMA to advocate on behalf of community oncology patients. Manage academic partnerships (Co PI on Grants with Dell Medical School and University of North Carolina using technology to enhance cancer care).</p> <p><i>Strategic Priorities:</i> Grow strategic Priorities: Advanced Practice Providers, Telehealth, Oral Oncolytics, Managed Care, Assist in reformulation of physician compensation model to incentivize productivity, value, and quality. Developing Advanced Practice Provider Strategy and Telehealth program. Working with team to develop and support oral oncolytics strategy. Working with managed care team to articulate our value proposition to payers and develop alternative payment model contracts to enhance value-based cancer care delivery.</p>
-------	--

- 2017- Full Clinical Professor, Dell Medical School at The University of Texas at Austin
Teach Medical Students Oncology sections of the curriculum.
Work with medical students on research projects to present at annual meetings.
Co-Principal investigator: Decision support in breast cancer.
Co-Principal Investigator: Use of dynamic MRI to evaluate early responders in breast cancer.
Co-Chair, Access to Care working group.
- 2016- Editor in Chief, Journal of Clinical Oncology – Clinical Cancer Informatics
Develop a look and feel for the new journal
Assemble an editorial board and a group of associate editors with complimentary informatics expertise.
Develop relationships with external stakeholder organizations to build the brand.
- 2016-2020 Service Line Lead, Breast Health, Division of Seton Women's Health Services, Dell Medical School at The University of Texas at Austin
Lead clinical integration of breast services leading up to a cancer diagnosis for Dell Medical School. Lead the NC3 committee and provide updates on breast health services. Integrate community stakeholders as it pertains to breast health.
- 2015-2021 Medical Director, Analytics, McKesson Speciality Health
Assist team to integrate analytic capabilities within the organization.
Works with team to identify new areas of growth, future retail models, manufacturer value proposition, needs of specialty programs, and identify operating model.
Facilitated transitioning from project directed approaches to sustained enterprise mindset with growth of disruptive industry solutions.
Evaluate external vendor relationships and vertical integration acquisitions to consider optimal growth strategies. Work with MCK and MSH toward a congruent McKesson 2021 analytics strategy.
Principal investigator for predictive analytics pilots to improve health outcomes and reduce total cost of care.
- 2007-2020 Medical Director, Pathways Task Force, The US Oncology Network and McKesson Specialty Health
Chair the breast cancer pathways and assist the task force in inclusion of therapeutic interventions with consideration of efficacy, toxicity, and value. Principal investigator on CVP clinical decision support tool demonstration of improved adherence to pathways prescribing by integrating the software platform into the electronic health record and process workflow at point of care.
- 2007-2018 Medical Director, Breast Cancer, Seton Family of Hospitals
Drive growth and quality of breast health services through the network by benchmarking operational and quality metrics.
Design and launch a breast center, and plan for national accreditation.
Lead multidisciplinary tumor boards for breast cancer.
Lead quality improvement projects for breast cancer for the network and report to the cancer committee.
- 2008-2015 Medical Director, Healthcare Informatics and HEOR, The US Oncology Network and McKesson Specialty Health
Business development from 2 studies at a time to 22 studies at a time.
Grew team of analysts and business development lead.
Developed an internal chart review process.
Developed streamlined process workflow and quality improvement processes.
Increased brand awareness of The Network through multiple presentations and publications.
- 2006-2007 Adjunct Professor, MD Anderson Cancer Center, Division of Cancer Medicine
Administered Young Investigators Award Grant to conduct health services research in elderly patients with breast cancer to evaluate long term toxicities associated with treatment.

Active Research:

- 2020 Evaluating electronic patient reported outcomes tools in community oncology practice
- 2018 Using clinical pharmacist initiated oral antiemetic protocols to control CINV and enhance value in cancer care
- 2018 Modeling predictive analytics to evaluate risk of hospitalization in patients with advanced cancer
- 2018 Evaluation of a patient decision aide to improve satisfaction among patients with breast cancer undergoing mastectomy. Lead PI: Dr. Clara Lee and Dr. Mike Pignone, Co-PI Dr. Debra Patt. Collaboration with UT Austin

2017	Implementation of advanced MRI in the community setting for predicting the response of breast cancer to neoadjuvant therapy. Lead PI: Dr. Thomas Yankeelov, Site PI: Dr. Debra Patt
2015	Utilizing clinical decision support systems within the electronic health record to facilitate compliance with evidence-based pathways for cancer care

C. LEADERSHIP, COMMITTEES, AND PHILANTHROPY

Leadership Development:

2017	Dell Medical School, Mentoring/Advising/Lecturing Mentoring Resident Nitya Rao on Disparities Health Services Research – Presented at ASCO Mentoring Undergraduate Student Sanica Metha on undergraduate narrative medicine project. Mentoring Andrew Gdowski Resident on Predictive Analytics Project
2015	Texas Oncology Leadership Development Program
2014-2016	McKesson Specialty Health Tier 3 Leadership Development Program Launched Telehealth Pilot in Texas Oncology
2013-2014	ASCO Leadership Development Program A year long program of young national leaders in oncology where we learned leadership development and partnership with stakeholders.
2013	McKesson Specialty Health Tier 2 Leadership Development Program

Lecturer

SURF Program, UT Dell Medical School
From Cells to Populations, UT Dell Medical School
Advocacy, UT School of Public Health

Board and Committee Activity:

2020-	ASCO Chair Breast Cancer Clinical Research Council
2020-	ASCO Telemedicine Task Force
2020-	ASCO Reopening task force
2019-	President, Texas Society of Clinical Oncology
2019-	Chair, Council on Legislation, Texas Medical Association
2017-	COA Payment Reform Committee
2017-	COA Government Relations Committee
2017-	ASCO EHR, technology, and data working group
2017-2020	ASCO Nominating Committee
2017	ASCO Education Committee
2016-	Texas Medical Association, Council on Legislation, Chair
2016-	Executive Committee, Community Oncology Alliance Board of Directors
2015-2017	Komen Austin Board of Directors
2015-2016	Texas Medical Association Committee on Science and Public Health
2014-2019	ASCO Payment Reform and Policy Committee
2014-2016	ASCO Clinical Practice Committee, Chair
2011-	Collaborative Care Committee, MSH
2011-	US Oncology National Policy Board
2011-2017	Patient Portal and Oncology Portal Working Group, MSH
2011-2016	Publications and Outcomes Committee Chair, MSH
2011-2014	Breast Cancer Resource Center Board of Directors
2009-2015	Texas Medical Association Cancer Committee, Chair
2008-	Pharmacy and Therapeutics Committee, USON
2006-	Advisory Council of the Texas Cancer Registry

Austin Philanthropy:

2020	Chair, Light The Night Campaign, The Leukemia & Lymphoma Society, Central Texas Chapter
2019-2020	Chair, Art Bra Austin, Breast Cancer Resource Center of Texas

2019	Chair, Survivorship Research for Young Adult Survivors of Breast Cancer, Breast Cancer Resource Center of Texas
2019	Chair, Fundraising event to raise funds to fund a research grant in oncology, Women Who Conquer Cancer

D. AWARDS AND HONORS

Awards:

2019	Fellow, American Society of Clinical Oncology
2018	Submitted as Co-Principal Investigator, Determining if a patient decision aide can increase satisfaction with surgical choices among patients undergoing mastectomy for breast cancer treatment. (Submitted with Dr. Mike Pignone and Dr. Clara Lee, UT Austin)
2018	Submitted as Co-Principal Investigator, NCI grant to use dynamic MRI to evaluate early response to chemotherapy in localized breast cancer (submitted with Dr. Thomas Yankeelov, UT Austin)
2014	Ruth Baines Young Physician of the Year Award, Travis County Medical Society
2006	American Society of Clinical Oncology Young Investigators Award
2006	American Society of Clinical Oncology Merit Award
2006	Research Fellow of the Year, MD Anderson Cancer Center
2006	Jesse Jones Fellowship in Cancer Education and Prevention at MD Anderson Cancer Center– the annual education and prevention award given to one fellow who has demonstrated excellence in these areas.

E. BIBLIOGRAPHY

- Patt, D, Goodwin J, Kuo, Y, Freeman J, Zhang D, Buccholz T, Hortobagyi G, Giordano S. Cardiac morbidity of adjuvant radiotherapy in patients with early-stage breast cancer. *J Clin Oncol*. 2005 Oct 20;23(30):7475-82. doi: 10.1200/JCO.2005.13.755. Epub 2005 Sep 12. PMID: 16157933
- Patt DA, Shopland DR, Anderson CM, Burns DM, Dunnington J, Gritz ER. Measuring progress to protect workers from job-related secondhand smoke in Texas. *Tex Med*. 2005 Dec;101(12):50-6. PMID: 17094502
- Patt D, Gauthier M, Giordano S. Paclitaxel in Breast Cancer. *Womens Health (Lond)*. 2006 Jan;2(1):11-21. doi: 10.2217/17455057.2.1.11. PMID: 19803922
- Patt D, Zhigang D, Shenying F, Hortobagyi G, Giordano S. Acute Myeloid Leukemia after Adjuvant Breast Cancer Therapy in Older Women: Understanding Risk. *J Clin Oncol*. 2007 Sep 1;25(25):3871-6. doi: 10.1200/JCO.2007.12.0832. Epub 2007 Jul 30. PMID: 17664457
- Scholl, P. Snyder, N. Patt, D. Talbott, B. Pilomatrical carcinosarcoma. *Otolaryngology Head and Neck Surgery* 2010 Nov;143(5 Suppl 3):S36-7. doi: 10.1016/j.otohns.2010.06.901. Epub 2010 Aug 16. PMID: 20970691
- Socinski MA, Raju RN, Stinchcombe T, Kocs DM, Couch LS, Barrera D, Rousey SR, Choksi JK, Jotte R, Patt DA, Periman PO, Schlossberg HR, Weissman CH, Wang Y, Asmar L, Pritchard S, Bromund J, Peng G, Treat J, Obasaju CK. Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer. *J Thorac Oncol*. 2010 Dec;5(12):1963-9. doi: 10.1097/JTO.0b013e3181fd42eb. PMID: 21102260
- Socinski, MA. Raju, RN. Stinchcombe, T. Kocs, DM. Couch, LS. Barrera, D. Rousey, SR. Choksi, JK. Jotte, R. Patt, DA. Periman, PO. Schlossberg, HR. Weissman, CH. Wang, Y. Asmar, L. Pritchard, S. Bromund J. Peng, G. Treat, J. Obasaju, CK. Randomized phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer *J Thorac Oncol* 2010
- Patt, D, Espirito, J, Turnwald, B, Hoang, S, Hoverman, J. Ixabepilone alone and in combination with chemotherapy in the community setting. *Proceedings ASCO Breast Cancer Symposium*. Abstract 204. 2010.

Neubauer, MA, Espirito, JL, Clayton, M, Patt, DA. Combination versus sequential chemotherapy for metastatic breast cancer: An evaluation of outcomes from a community oncology network. *JCO* 28:15s, 2010 (suppl; abstr 6106).

O'Shaughnessy, J, Osborne, C, Pippen, JE, Yoffe, M, Patt, D, Rocha C, Koo, IC, Sherman BM, Bradley, C. Iniparib plus Chemotherapy n Metastatic Triple-Negative Breast Cancer. *N Engl J Med*. 2011 Jan 20;364(3):205-14. doi: 10.1056/NEJMoa1011418. Epub 2011 Jan 5. PMID: 21208101

Hoverman, JR, Cartwright TH, Patt, DA, Espirito, JL, Clayton, MP, Garey, JS, Kopp, TJ, Kolodziej, M, Neubauer, M, Fitch, K, Pyenson, B, Beveridge, RA. Pathways, Outcomes, and Costs in Colon Cancer: Retrospective evaluations in two distinct databases. *Am J Manag Care*. 2011 May;17 Suppl 5 Developing:SP45-52. PMID: 21711077

Hoverman JR, Cartwright TH, Patt DA, Espirito JL, Clayton MP, Garey JS, Kopp TJ, Kolodziej M, Neubauer MA, Fitch K, Pyenson B, Beveridge RA. Pathways, outcomes, and costs in colon cancer: retrospective evaluations in two distinct databases. *J Oncol Pract*. 2011 May;7(3 Suppl):52s-9s. doi: 10.1200/JOP.2011.000318. PMID: 21886520

Ginsburg A, Patt D, Flinn J, Espirito J, Neubauer M, Cartwright T, Hoverman J, Busby B, Brooks, B, Kolodziej M, Sitarik M, Anderson R, Beveridge R. Understanding male breast cancer in the community setting. *ASCO MEETING ABSTRACTS* Jun 9, 2011:e16526 Published in JCO supplements

Chen C, Patt D, Kazzaz D, Shankleton J, Forsyth M, Ganesh R. Evaluating utilization characteristics for the Oncotype DX recurrence score in early-stage breast cancer. Jun 9, 2011:625. Published in JCO supplements

Patt D, Espirito J, Turnwald B, Hoverman J, Neubauer M, Cartwright T, Brooks B, Busby L, Sitarik M, Kolodziej M, Ginsburg A, Sheth S, Garey J, Clayton M, Nelson R, Anderson R, Beveridge R. Utilization and relative value of breast cancer adjuvant chemotherapy regimens in the community. Jun 9, 2011:e16595. Published in JCO supplements

Kolodziej M, Hoverman JR, Garey JS, Espirito J, Sheth S, Ginsburg A, Neubauer MA, Patt D, Brooks B, White C, Sitarik M, Anderson R, Beveridge R. Benchmarks for value in cancer care: an analysis of a large commercial population. *J Oncol Pract*. 2011 Sep;7(5):301-6. doi: 10.1200/JOP.2011.000394. PMID: 22211126

Patt D, Espirito J, Turnwald B, Hoverman J, Neubauer M, Busby L, Brooks, Kolodziej, Anderson R, Beveridge R. Utilization of pegfilgrastim in adjuvant chemotherapy regimens for breast cancer in the community. Sep 30, 2011:213 Published in JCO supplements

Patt D, Espirito J, Turnwald B, Hoverman J, Neubauer M, Cartwright T, Busby L, Brooks B, Sitarik M, Kolodziej M, Beveridge R. Changes in adjuvant breast cancer chemotherapy regimen selection over time in the community. May 30, 2012:6109. Published in JCO supplements

Brow M, Okon T, George E, Eagle D, Patt D, Gould B, Brooks B, Cobb P, White C, Tetrault S, Beveridge R. Thoughts and recommendations on cancer care site of service. *Community Oncology* 2012 9(2) pages 382-385.

Reeder-Hayes K, Filip E, Patt D, Jaffee E. Women in oncology. *Am Soc Clin Oncol Educ*. Book 2013;448-55. doi: 10.14694/EdBook_AM.2013.33.448. PMID: 23714569

Brow M, Hoverman JR, Patt D, Herman B, Verrilli D, Garey J, Beveridge R. Defining cancer care quality or delivering quality cancer care? *J Natl Compr Canc Netw*. 2013 Feb 1;11(2):121-4. doi: 10.6004/jnccn.2013.0019. PMID: 23411378

Chen, C, Dhanda, R, Tseng, W, Forsyth, M, Patt, D. Evaluating Use Characteristics for the Oncotype DX 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer. *J Oncol Pract* Feb 2013 Jul;9(4):182-7. doi: 10.1200/JOP.2012.000638. Epub 2013 Feb 12. PMID: 23942918

Ramsey SD, Sullivan SD, Reed SD, Tina Shih YC, Schaecher K, Dhanda R, Patt D, Pendergrass K, Walker M, Malin J, Schwartzberg L, Neumann K, Yu E, Ravelo A, Small A. Oncology comparative effectiveness research: a multistakeholder perspective on principles for conduct and reporting. *Oncologist* 2013 Jun;18(6):760-7. doi: 10.1634/theoncologist.2012-0386. Epub 2013 May 6. PMID: 23650020

Fryefield DC, Staggs S, Herman W, Stickler A, Ahmad A, Patt DA, Beveridge RA. Achieving the Meaningful Use Standard: A Model for Implementing Change Within Medical Practices. *J Oncol Pract*. 2014 Mar;10(2):105. doi: 10.1200/JOP.2013.001105. PMID: 29452558

Ramakrishna N, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Giordano SH, Gonzalez-Angulo AM, Kirshner JJ, Krop I, Levinson J, Modi S, Patt DA, Perez EA, Perlmutter J, Winer EP, Lin NU. Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol*. 2014 Jul 1;32(19):2100-8. doi: 10.1200/JCO.2013.54.0955. Epub 2014 May 5. PMID: 24799487

Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Gonzalez-Angulo AM, Krop I, Levinson J, Lin NU, Modi S, Patt DA, Perez EA, Perlmutter J, Ramakrishna N, Winer EP; American Society of Clinical Oncology. Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol*. 2014 Jul 1;32(19):2078-99. doi: 10.1200/JCO.2013.54.0948. Epub 2014 May 5. PMID: 24799465

Patt DA. Taking on racial and ethnic disparities in cancer care. *J Community and Supportive Oncology* 2014

Patt D, Rembert D, Corzo D. Treatment of metastatic breast cancer with nab-paclitaxel in the community practice setting: a US Oncology survey. *J Community Support Oncol*. 2015 May;13(5):173-80. doi: 10.12788/jcso.0132. PMID: 26029934

Yasenchak CA, Tseng WY, Yap M, Rembert D, Patt DA. Economic impact of disease progression following front-line therapy in classical Hodgkin lymphoma. *Leuk Lymphoma* 2015;56(11):3143-9. doi: 10.3109/10428194.2015.1030639. Epub 2015 May 18. PMID: 25860233

Kumar SK, Ma E, Engebretson AE, Buadi FK, Lacy MQ, Dispenzieri A, Duh MS, Lafeuille MH, Lefebvre P, Cheng WY, Dea K, Rembert D, Patt D, Niculescu L, Quick M, Rajkumar SV. Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma. *Leukemia*. 2016 Apr;30(4):995-8. doi: 10.1038/leu.2015.225. Epub 2015 Aug 14. PMID: 26271606

Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. *J Clin Oncol*. 2015 Jun 10;33(17):1889-94. doi: 10.1200/JCO.2014.56.2736. Epub 2015 Feb 9. PMID: 25667295

Henry NL, Patt DA, Meyers MO, Malik M, Bretsch J, Jackson C, Grupe A, Von Roenn J. Bridging the Medical Education and Quality Cancer Care Divide: A Call to Action. *J Oncol Pract*. 2015 Sep;11(5):424-6. doi: 10.1200/JOP.2015.004242. Epub 2015 Jun 30. PMID: 26130819

Di Bella NJ, Bhowmik D, Bhor M, Yap M, Middlebrook B, Rembert D, Cain Z, Okoro T, Bolinder B, Patt D, Jabbour EJ. The Effectiveness of Tyrosine Kinase Inhibitors and Molecular Monitoring Patterns in Newly Diagnosed Patients With Chronic Myeloid Leukemia in the Community Setting. *Clin Lymphoma Myeloma Leuk*. 2015 Oct;15(10):599-605. doi: 10.1016/j.clml.2015.06.006. Epub 2015 Jun 19. PMID: 26208445

Denduluri N, Patt DA, Wang Y, Bhor M, Li X, Favret AM, Morrow PK, Barron RLRL, Asmar L, Saravanan S, Li Y, Garcia J, Lyman GH. Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices. *J Natl Compr Canc Netw*. 2015 Nov;13(11):1383-93. doi: 10.6004/jnccn.2015.0166. PMID: 26553767

Liang C, Li L, Fraser CD, Ko A, Corzo D, Enger C, Patt D. The treatment patterns, efficacy, and safety of nab-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis. *BMC Cancer* 2015 Dec 29;15:1019. doi: 10.1186/s12885-015-2027-x. PMID: 26714468

Patt D. Better Screening Using Big Data. *J Oncol Pract* 2016 Aug; 12(8): 699-700. PMID: 27382002

Agiro A, Ma Q, Acheson AK, Wu SJ, Patt DA, Baron JJ, Malin J, Schilsky RL, Lyman GH. Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors with Chemotherapy for Breast Cancer. *J Clin Oncol* 2016 Nov 10;34(32):3872-3879. doi: 10.1200/JCO.2016.67.2899. Epub 2016 Sep 30. PMID: 27646945

- Cooke KJ, Patt DA, Prabhu RS. The Road of Mentorship. *Am Soc Clin Oncol Educ Book*. 2017;37:788-792. doi: 10.1200/EDBK_175193. PMID: 28561670
- Patt DA, Bernstam EV, Mandel JC, Kreda DA, Warner JL. More Medicine, Fewer Clicks: How Informatics Can Actually Help Your Practice. *Am Soc Clin Oncol Educ Book*. 2017;37:450-459. doi: 10.1200/EDBK_174891. PMID: 28561658
- Robert NJ, Goertz HP, Chopra P, Jiao X, Patt D, Antao V. Her 2-positive metastatic breast cancer patients receiving pertuzumab in a community oncology practice setting: Treatment patterns and outcomes. *Drugs Real World Outcomes* 2017 Mar;4(1):1-7. doi: 10.1007/s40801-016-0102-5. PMID: 28063028
- Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, Wildiers H, Hudis CA, O'Shaughnessy J, Zamora E, Yardley DA, Frenzel M, Koustenis A, Baselga J. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR +/HER2 - Metastatic Breast Cancer. *Clin Cancer Res*. 2017 Sep 1;23(17):5218-5224. doi: 10.1158/10780432.CCR-17-0754. Epub 2017 May 22. PMID: 28533223
- Patt D., Our Journey Begins. *JCO Clin Cancer Inform*. 2017 Nov;1:1-2. doi: 10.1200/CCI.16.00063. PMID: 30657367
- Virostko J, Hainline A, Kang H, Arlinghaus LR, Abramson RG, Barnes SL, Blume JD, Avery S, Patt D, Goodgame B, Yankeelov TE, Sorace AG. Dynamic contrast enhanced magnetic resonance imaging and diffusion-weighted magnetic resonance imaging for predicting the response of locally advanced breast cancer to neoadjuvant therapy: a meta-analysis. *J Med Imaging (Bellingham)*. 2018 Jan;5(1):011011. doi: 10.1117/1.JMI.5.1.011011. Epub 2017 Nov 24. PMID: 29201942
- Patt D, Page R. Measuring Quality Is Complicated. *J Oncol Pract*. 2018 Jan;14(1):1-2. doi: 10.1200/JOP.2017.027789. Epub 2017 Dec 6. PMID: 29211577
- Martin M, Holmes FA, Ejlersen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group (Patt D). Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebocontrolled, phase 3 trial. *Lancet Oncol*. 2017 Dec;18(12):1688-1700. doi: 10.1016/S14702045(17)30717-9. Epub 2017 Nov 13. PMID: 29146401
- Patt DA. Utilization management in oncology. *J Clin Oncol*. 2017;35 (suppl 8S; abstract 172).
- Denduluri N, Lyman GH, Wang Y, Morrow PK, Barron R, Patt D, Bhowmik D, Li X, Bhor M, Fox P, Dhanda R, Saravanan S, Jiao X, Garcia J, Crawford J. Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer. *Clin Breast Cancer*. 2018 Oct;18(5):380-386. doi: 10.1016/j.clbc.2018.02.003. Epub 2018 Feb 16. PMID: 29622384
- Sorace AG, Wu C, Barnes SL, Jarrett AM, Avery S, Patt D, Goodgame B, Luci JJ, Kang H, Abramson RG, Yankeelov TE, Virostko J. Repeatability, reproducibility, and accuracy of quantitative mri of the breast in the community radiology setting. *J Magn Reson Imaging*. 2018 Mar 23;10.1002/jmri.26011. doi: 10.1002/jmri.26011. Online ahead of print. PMID: 29570895
- Patt DA. Understanding Utilization Management Policy: How to Manage This Increasingly Complex Environment in Collaboration and With Better. *Am Soc Clin Oncol Educ Book*. 2018 May 23;38:135-138. doi: 10.1200/EDBK_200891. Review. PMID: 30231339
- Patt D. Debra Patt on How the Management of Cancer is Changing as Patients Live Longer. *Oncology (Williston Park)*. 2018 Jun;32(6):274-5. PMID: 29940056
- Warner JL, Patt DA. Cancer Informatics in 2017: A New Beginning and a Bright Future. Section Editors for the IMIA Yearbook Section on Cancer Informatics. *Yearb Med Inform*. 2018 Aug;27(1):223-226. doi: 10.1055/s-0038-1667086. Epub 2018 Aug 29. PMID: 30157527

Giordano SH, Temin S, Chandarlapaty S, Crews JR, Esteva FJ, Kirshner JJ, Krop IE, Levinson J, Lin NU, Modi S, Patt DA, Perlmutter J, Ramakrishna N, Winer EP, Davidson NE. Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update. *J Clin Oncol*. 2018 Sep 10;36(26):2736-2740. doi: 10.1200/JCO.2018.79.2697. Epub 2018 Jun 25. PMID: 29939838

Ramakrishna N, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Giordano SH, Kirshner JJ, Krop IE, Levinson J, Modi S, Patt DA, Perlmutter J, Winer EP, Lin NU. Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. *J Clin Oncol*. 2018 Sep 20;36(27):2804-2807. doi: 10.1200/JCO.2018.79.2713. Epub 2018 Jun 25. PMID: 29939840

Patt D, Stella P, Bosserman L. Clinical Challenges and Opportunities With Current Electronic Health Records: Practicing Oncologists' Perspective. *J Oncol Pract*. 2018 Oct;14(10):577-579. doi: 10.1200/JOP.18.00306. Epub 2018 Sep 12. PMID: 30207855

Gordan LN, Patt D. Recent study on site of care has severe limitations. *Am J Manag Care*. 2018 Oct;24(10):450. PMID: 30325184 Virostko J, Sorace AG, Wu C, Ekrot D, Jarrett AM, Upadhyaya RM, Avery S, Patt D, Goodgame B, Yankeelov TE. Magnetization Transfer MRI of Breast Cancer in the Community Setting: Reproducibility and Preliminary Results in Neoadjuvant Therapy. *Tomography*. 2019 Mar;5(1):44-52. doi: 10.18383/j.tom.2018.00019. PMID: 30854441

Henneghan AM, Becker H, Harrison ML, Inselmann K, Fico B, Schafer H, King E, Patt D, Kesler S. A randomized control trial of meditation compared to music listening to improve cognitive function for breast cancer survivors: Feasibility and acceptability. *Complement Ther Clin Pract*. 2020 Nov;41:101228. doi: 10.1016/j.ctcp.2020.101228. Epub 2020 Sep 11. PMID: 32949954

Parikh RB, Gdowski A, Patt DA, Hertler A, Mermel C, Bekelman JE . Using Big Data and Predictive Analytics to Determine Patient Risk in Oncology. *Am Soc Clin Oncol Educ Book*. 2019 Jan;39:e53-e58. doi: 10.1200/EDBK_238891. Epub 2019 May 17. PMID: 31099672

Oliveira M, Saura C, Nuciforo P, Calvo I, Andersen J, Passos-Coelho JL, Gil Gil M, Bermejo B, Patt DA, Ciruelos E, de la Peña L, Xu N, Wongchenko M, Shi Z, Singel SM, Isakoff SJ. FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer. *Ann Oncol*. 2019 May 30. pii: mdz177. doi: 10.1093/annonc/mdz177. [Epub ahead of print] PMID: 31147675

Crawford J, Denduluri N, Patt D, Jiao X, Morrow PK, Garcia J, Barron R, Lyman GH. Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer. *Support Care Cancer*. 2020 Feb;28(2):925-932. doi: 10.1007/s00520-019-04875-1. Epub 2019 Jun 7. PMID: 31172284

Warner JL, Patt D; Section Editors for the IMIA Yearbook Section on Cancer Informatics. *Cancer Informatics in 2018: The Mysteries of the Cancer Genome Continue to Unravel, Deep Learning Approaches the Clinic, and Passive Data Collection Demonstrates Utility*. *Yearb Med Inform* 2019 Aug;28(1):236-238. doi: 10.1055/s-0039-1677931. Epub 2019 Aug 16. PMID: 31419838

Patt D, Rosenberg J. How obesity affects cancer treatment-and how to talk with patients about prevention. *Am J Manag Care*. 2019 Oct;25(11 Spec No.):SP336-SP337. PMID: 31860247

Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators (Patt D). Pembrolizumab for Early Triple-Negative Breast Cancer. *N Engl J Med*. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549. PMID: 32101663

Patt D. Using Clinical Informatics to Navigate a Crisis: How Technology and Policy Change Can Influence Cancer Care Delivery. *JCO Clin Cancer Inform*. 2020 Apr;4:318-320. doi: 10.1200/CCI.20.00033. PMID: 32282231

Jarrett AM, Faghihi D, Li DAH, Lima EABF, Virostko J, Biros G, Patt D, Yankeelov TE. Optimal Control Theory for Personalized Therapeutic Regimens in Oncology: Background, History, Challenges, and Opportunities. *J Clin Med*. 2020 May 2;9(5):1314. doi: 10.3390/jcm9051314. PMID: 32370195

Rugo HS, Dieras V, Cortes J, Patt D, Wildiers H, O'Shaughnessy J, Zamora E, Yardley DA, Carter GC, Sheffield KM, Li L, Andre VAM, Li XI, Frenzel M, Huang YJ, Dickler MN, Tolaney SM. Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving singleagent chemotherapy—a comparison with MONARCH 1. *Breast Cancer Res Treat*. 2020 Aug 12. doi: 10.1007/s10549-020-05838-5. Online ahead of print. PMID: 32789591

Warner JL, Patt D; Section Editors for the IMIA Yearbook Section on Cancer Informatics. *Cancer Informatics in 2019: Deep Learning Takes Center Stage*. *Yearb Med Inform*. 2020 Aug;29(1):243-246. doi: 10.1055/s-0040-1701993. Epub 2020 Aug 21. PMID: 32823323

Seligson ND, Warner JL, Dalton WS, Martin D, Miller RS, Patt D, Kehl KL, Palchuk MB, Alterovitz G, Wiley LK, Huang M, Shen F, Wang Y, Nguyen KA, Wong AF, Meric-Bernstam F, Bernstam EV, Chen JL. Recommendations for patient similarity classes: results of the AMIA 2019 workshop on defining patient similarity. *J Am Med Inform Assoc*. 2020 Sep 4:ocaa159. doi: 10.1093/jamia/ocaa159. Online ahead of print. PMID: 32885823

Chan A, Moy B, Mansi J, Ejlersen B, Holmes FA, Chia S, Iwata H, Gnant M, Loibl S, Barrios CH, Somali I, Smichkoska S, Martinez N, Alonso MG, Link JS, Mayer IA, Cold S, Murillo SM, Senecal F, Inoue K, Ruiz-Borrego M, Hui R, Denduluri N, Patt D, Rugo HS, Johnston SRD, Bryce R, Zhang B, Xu F, Wong A, Martin M; ExteNET Study Group. Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. *Clin Breast Cancer*. 2020 Oct 6:S1526-8209(20)302585. doi: 10.1016/j.clbc.2020.09.014. Online ahead of print. PMID: 33183970

Patt D, Gordan L, Diaz M, Okon T, Grady L, Harmison M, Markward N, Sullivan M, Peng J, Zhou A. Impact of COVID-19 on Cancer Care: How the Pandemic Is Delaying Cancer Diagnosis and Treatment for American Seniors. *JCO Clin Cancer Inform*. 2020 Nov;4:1059-1071. doi: 10.1200/CCI.20.00134. PMID: 33253013

Jarrett AM, Hormuth DA 2nd, Wu C, Kazerouni AS, Ekrut DA, Virostko J, Sorace AG, DiCarlo JC, Kowalski J, Patt D, Goodgame B, Avery S, Yankeelov TE. Evaluating patient-specific neoadjuvant regimens for breast cancer via a mathematical model constrained by quantitative magnetic resonance imaging data. *Neoplasia*. 2020 Dec;22(12):820-830. doi: 10.1016/j.neo.2020.10.011. Epub 2020 Nov 14. PMID: 33197744

Patt D, Wilfong L, Kanipe K, Paulson RS. Telemedicine for cancer care: implementation across a multicenter community oncology practice. *Am J Manag Care*. 2020 Dec;26(10 Spec No.):SP330-SP332. doi: 10.37765/ajmc.2020.88560. PMID: 33395240

Pennell NA, Dillmon M, Levit LA, Moushey EA, Alva AS, Blau S, Cannon TL, Dickson NR, Diehn M, Gonen M, Gonzalez MM, Hensold JO, Hinyard LJ, King T, Lindsey SC, Magnuson A, Marron J, McAneny BL, McDonnell TM, Mileham KF, Nasso SF, Nowakowski GS, Oettel KR, Patel MI, Patt DA, Perlmutter J, Pickard TA, Rodriguez G, Rosenberg AR, Russo B, Szczepanek C, Smith CB, Srivastava P, Teplinsky E, Thota R, Traina TA, Zon R, Bourbeau B, Bruinooge SS, Foster S, Grubbs S, Hagerty K, Hurley P, Kamin D, Phillips J, Schenkel C, Schilsky RL, Burris HA 3rd. American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care. *J Clin Oncol*. 2020 Dec 8;JCO2002953. doi: 10.1200/JCO.20.02953. Online ahead of print. PMID: 33290128

Hormuth DA 2nd, Jarrett AM, Lorenzo G, Lima EABF, Wu C, Chung C, Patt D, Yankeelov TE. Math, magnets, and medicine: enabling personalized oncology. *Expert Rev Precis Med Drug Dev*. 2021;6(2):79-81. doi: 10.1080/23808993.2021.1878023. Epub 2021 Jan 27. PMID: 34027102

Pennell NA, Dillmon M, Levit LA, Moushey EA, Alva AS, Blau S, Cannon TL, Dickson NR, Diehn M, Gonen M, Gonzalez MM, Hensold JO, Hinyard LJ, King T, Lindsey SC, Magnuson A, Marron J, McAneny BL, McDonnell TM, Mileham KF, Nasso SF, Nowakowski GS, Oettel KR, Patel MI, Patt DA, Perlmutter J, Pickard TA, Rodriguez G, Rosenberg AR, Russo B, Szczepanek C, Smith CB, Srivastava P, Teplinsky E, Thota R, Traina TA, Zon R, Bourbeau B, Bruinooge SS, Foster S, Grubbs S, Hagerty K, Hurley P, Kamin D, Phillips J, Schenkel C, Schilsky RL, Burris HA 3rd. American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care. *J Clin Oncol*. 2021 Jan 10;39(2):155-169. doi: 10.1200/JCO.20.02953. Epub 2020 Dec 8. PMID: 3329

Virostko J, Kuketz G, Higgins E, Wu C, Sorace AG, DiCarlo JC, Avery S, Patt D, Goodgame B, Yankeelov TE. The rate of breast fibroglandular enhancement during dynamic contrast-enhanced MRI reflects response to neoadjuvant therapy. *Eur J Radiol*. 2021 Mar;136:109534. doi: 10.1016/j.ejrad.2021.109534. Epub 2021 Jan 9. PMID: 33454460

Patt DA, Wilfong L, Toth S, Broussard S, Kanipe K, Hammonds J, Allen V, Mautner B, Campbell N, Dubey AK, Wu N, Neubauer M, Jones BS, Paulson RS. Telemedicine in Community Cancer Care: How Technology Helps Patients With Cancer Navigate a Pandemic. *JCO Oncol Pract*. 2021 Jan;17(1):e11-e15. doi: 10.1200/OP.20.00815.PMID: 33434450

Thomas CA, Hirschorn AM, Tomkins JE, Birch WE, Bosserman LD, Patt DA, Patel DR, Diaz M, Marsland TA, Klux MM, Balaban EP, Blanchard EM, Franklin GE, Seth R, Norden A. New Landscape: Physician Compensation. *JCO Oncol Pract*. 2021 Apr;17(4):186-189. doi: 10.1200/OP.20.00788. Epub 2020 Dec 22.PMID: 33351676

Patt D, Wilfong L, Hudson KE, Patel A, Books H, Pearson B, Boren R, Patil S, Olson-Celli K, Basch E. Implementation of Electronic Patient-Reported Outcomes for Symptom Monitoring in a Large Multisite Community Oncology Practice: Dancing the Texas TwoStep Through a Pandemic. *JCO Clin Cancer Inform*. 2021 May;5:615-621. doi: 10.1200/CCI.21.00063.PMID: 34085537

Tolaney SM, Kalinsky K, Kaklamani VG, D'Adamo DR, Aktan G, Tsai ML, O'Regan RM, Kaufman PA, Wilks ST, Andreopoulou E, Patt DA, Yuan Y, Wang G, Savulsky C, Xing D, Kleynerman E, Karantza V, Diab S. Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study. *Clin Cancer Res*. 2021 Jun 1;27(11):3061- 3068. doi: 10.1158/10780432.CCR-20-4726. Epub 2021 Mar 16.PMID: 33727258

Patt D, Wilfong L, Hudson KE, Patel A, Books H, Pearson B, Boren R, Patil S, Olson-Celli K, Basch E. Implementation of Electronic Patient-Reported Outcomes for Symptom Monitoring in a Large Multisite Community Oncology Practice: Dancing the Texas TwoStep Through a Pandemic. *JCO Clin Cancer Inform*. 2021 May;5:615-621. doi: 10.1200/CCI.21.00063.PMID: 34085537

Slavkova KP, DiCarlo JC, Kazerouni AS, Virostko J, Sorace AG, Patt D, Goodgame B, Yankeelov TE. Slavkova KP, et al. Among authors: patt d. Characterizing Errors in Pharmacokinetic Parameters from Analyzing Quantitative Abbreviated DCE-MRI Data in Breast Cancer. *Tomography*. 2021 Jun 23;7(3):253-267. doi: 10.3390/tomography7030023. *Tomography*. 2021. PMID: 34201654

Zon RT, Kennedy EB, Adelson K, Blau S, Dickson N, Gill D, Laferriere N, Lopez AM, Mulvey TM, Patt D, Pickard TA, Purdom T, Royce TJ, Sumrall AL, Page RD. Telehealth in Oncology: ASCO Standards and Practice Recommendations. *JCO Oncol Pract*. 2021 Sep;17(9):546-564. doi: 10.1200/OP.21.00438. Epub 2021 Jul 28.PMID: 34838096

Zon RT, Kennedy EB, Adelson K, Blau S, Dickson N, Gill D, Laferriere N, Lopez AM, Mulvey TM, Patt D, Pickard TA, Purdom T, Royce TJ, Sumrall AL, Page RD. Telehealth in Oncology: ASCO Standards and Practice Recommendations. *JCO Oncol Pract*. 2021 Sep;17(9):546-564. doi: 10.1200/OP.21.00438. Epub 2021 Jul 28.PMID: 34319760

Bakouny Z, Patt DA. Machine Learning and Real-World Data: More than Just Buzzwords. *JCO Clin Cancer Inform*. 2021 Aug;5:811813. doi: 10.1200/CCI.21.00092.PMID: 34383581

Angela M. Jarrett, Anum S. Kazerouni, Chengyue Wu, John Virostko, Anna G. Sorace, Julie C. DiCarlo, David A. Hormuth II, David A. Ekrut, Debra Patt. Quantitative magnetic resonance imaging and tumor forecasting of breast cancer patients in the community setting. *Nature Protocols* (2021). Published: 22 September 2021

Robin T. Zon , MD; Erin B. Kennedy , MHSc; Kerin Adelson, MD; Sibel Blau, MD; Natalie Dickson , MD; David Gill , MD; Nicole Laferriere, MD; Ana Maria Lopez, MD, MPH; Therese M. Mulvey , MD; Debra Patt , MD; Todd A. Pickard, MMS; Terry Purdom; Trevor J. Royce , MD, MS, MPH; Ashley L. Sumrall , MD; and Ray D. Page , DO, PhD. Telehealth in Oncology: ASCO Standards and Practice Recommendations. DOI: 10.1200/OP.21.00438 *JCO Oncology Practice* 17, no. 9 (September 01, 2021) 546-564

Harbeck N, Rastogi P, Martin M, Tolaney SM, Shao ZM, Fasching PA, Huang CS, Jaliffe GG, Tryakin A, Goetz MP, Rugo HS, Senkus E, Testa L, Andersson M, Tamura K, Del Mastro L, Steger GG, Kreipe H, Hegg R, Sohn J, Guarneri V, Cortés J, Hamilton E, André V, Wei R, Barriga S, Sherwood S, Forrester T, Munoz M, Shahir A, San Antonio B, Nabinger SC, Toi M, Johnston SRD, O'Shaughnessy J; monarchE Committee Members Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. *Ann Oncol*. 2021 Dec;32(12):1571-1581. doi: 10.1016/j.annonc.2021.09.015. Epub 2021 Oct 14. PMID: 34656740 *Clinical Trial*.

Jarrett AM, Kazerouni AS, Wu C, Virostko J, Sorace AG, DiCarlo JC, Hormuth DA 2nd, Ekru DA, Patt D, Goodgame B, Avery S, Yankeelov TE. Quantitative magnetic resonance imaging and tumor forecasting of breast cancer patients in the community setting. *Nat Protoc.* 2021 Nov;16(11):5309-5338. doi: 10.1038/s41596-021-00617-y. Epub 2021 Sep 22. PMID: 34552262

Virostko J, Sorace AG, Slavkova KP, Kazerouni AS, Jarrett AM, DiCarlo JC, Woodard S, Avery S, Goodgame B, Patt D, Yankeelov TE. Quantitative multiparametric MRI predicts response to neoadjuvant therapy in the community setting. *Breast Cancer Res.* 2021 Nov 27;23(1):110. doi: 10.1186/s13058-021-01489-6. PMID: 34838096

Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. *N Engl J Med.* 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651. PMID: 35139274 Clinical Trial.

Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. *N Engl J Med.* 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651. PMID: 35139274 Clinical Trial. Patt D, Gordan L, Patel K, Okon T, Ferreyros N, Markward N, Sullivan M, Burnett B, Getachew B, Harris C. Considerations to increase rates of breast cancer screening across populations. *Am J Manag Care.* 2022 Apr;28(3 Spec. No.):SP136-SP138. doi: 10.37765/ajmc.2022.88855. Epub 2022 Mar 14. PMID: 35285592

Patt D, Liu X, Li B, McRoy L, Layman RM, Brufsky A. Real-World Treatment Patterns and Outcomes of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis. *Clin Breast Cancer.* 2022 May 5:S1526-8209(22)00081-7. doi: 10.1016/j.clbc.2022.05.002. Online ahead of print. PMID: 35643624

Giordano SH, Franzoi MAB, Temin S, Anders CK, Chandarlapaty S, Crews JR, Kirshner JJ, Krop IE, Lin NU, Morikawa A, Patt DA, Perlmutter J, Ramakrishna N, Davidson NE. Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2 Breast Cancer: ASCO Guideline Update. *J Clin Oncol.* 2022 May 31;JCO2200519. doi: 10.1200/JCO.22.00519. Online ahead of print. PMID: 35640077

Ramakrishna N, Anders CK, Lin NU, Morikawa A, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Franzoi MAB, Kirshner JJ, Krop IE, Patt DA, Perlmutter J, Giordano SH. Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update. *J. Clin Oncol.* 2022 May 31;JCO2200520. doi: 10.1200/JCO.22.00520. Online ahead of print. PMID: 35640075

Wu C, Lorenzo G, Hormuth DA 2nd, Lima EABF, Slavkova KP, DiCarlo JC, Virostko J, Phillips CM, Integrating mechanism-based modeling with biomedical imaging to build practical digital twins for clinical oncology. (Melville). 2022 Jun;3(2):021304. doi: 10.1063/5.0086789. Epub 2022 May 17. PMID: 35602761 Review. *Biophys Rev*